Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Chronic constipation, a prevalent gastrointestinal disorder with limited treatment efficacy in refractory cases, has prompted exploration of fecal microbiota transplantation (FMT) as a novel therapeutic strategy. This systematic review and meta-analysis evaluate the efficacy, safety, and gut microbial dynamics of FMT in adults with chronic constipation.
Methods: We systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to January 2025, identifying 1,072 records. Nine studies ( = 245 patients) met inclusion criteria for qualitative synthesis, with eight contributing to meta-analysis. Outcomes included constipation remission and improvement, stool metrics, quality of life, and microbiota changes. Random-effects models analyzed pooled remission rates, mean differences (MDs), and heterogeneity (I statistics).
Results: Fecal microbiota transplantation achieved a 50.7% pooled remission rate (95% CI: 38.7%-62.7%) and 64.8% improvement rate (95% CI: 51.4%-76.3%). Significant improvements were observed in stool consistency (MD = 1.32, 95% CI: 1.05-1.35), quality of life (GIQLI MD = 32.19, 95% CI: 17.15-47.23), and symptom severity (Wexner MD = -4.83, 95% CI: -7.15-2.51). Post-FMT microbiota analyses revealed enrichment of beneficial taxa (Bifidobacterium, Prevotella; Firmicutesacteroidetes) and suppression of pro-inflammatory Enterobacteriaceae. Transient gastrointestinal adverse events (e.g., bloating: 17.3%) resolved spontaneously, with no severe complications reported.
Conclusion: Fecal microbiota transplantation demonstrates clinically meaningful symptom relief and gut microbiota remodeling in chronic constipation, supported by favorable short-term safety. While heterogeneity in protocols and limited RCT data warrant caution, these findings advocate standardized FMT frameworks and confirmatory trials to optimize therapeutics for refractory constipation.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42025643634.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12350361 | PMC |
| http://dx.doi.org/10.3389/fmicb.2025.1604571 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection.
BMC Microbiol
September 2025
Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.
Background: A plant-focused, healthy dietary pattern, such as the Mediterranean diet enriched with dietary fiber, polyphenols, and polyunsaturated fats, is well known to positively influence the gut microbiota. Conversely, a processed diet high in saturated fats and sugars negatively impacts gut diversity, potentially leading to weight gain, insulin resistance, and chronic, low-grade inflammation. Despite this understanding, the mechanisms by which the Mediterranean diet impacts the gut microbiota and its associated health benefits remain unclear.
View Article and Find Full Text PDF[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)].
Bull Cancer
September 2025
Service d'hématologie, département d'oncologie, hôpitaux universitaire de Genève (HUG), faculté de médecine, université de Genève, Genève, Suisse. Electronic address:
Acute graft-versus-host disease (GVHDa) is one of the leading causes of morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT) patients. While the first-line consensus treatment has been based on systemic corticosteroid therapy for many years, ruxolitinib has recently been approved and has become the standard second-line treatment. Nevertheless, the effectiveness of ruxolitinib remains limited to 40 % of cortico-resistant patients, raising the crucial question of selecting a third-line treatment.
View Article and Find Full Text PDFMicrobiota-Dependent Fiber Responses: A Proof-of-Concept Study on Short-chain Fatty Acid Production in Prevotella- and Bacteroides-Dominated Healthy Individuals.
J Nutr
September 2025
Institute of Food and One Health, Leibniz University Hannover, 30167 Hannover, Germany.
Background: Dietary fiber supports metabolic health via microbial fermentation, producing short-chain fatty acids (SCFAs). However, metabolic responses to fiber vary between individuals, potentially due to differences in gut microbiota composition. The Prevotella-to-Bacteroides (P/B) ratio has emerged as a potential biomarker for fiber responsiveness.
View Article and Find Full Text PDFInsights into gut microbiota and metabolite profiles during in vitro fermentation of Volvaria volvacea polysaccharides: unraveling the central role of Bacteroides thetaiotaomicron.
Food Chem
September 2025
State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, Jiangsu 214122, China; School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China; International Joint Research Laboratory for Probiotics, Jiangnan University, Wuxi, Jiangsu 214122, China. Ele
Volvaria volvacea polysaccharides (VVP) possess diverse bioactivities with promising applications in biomedicine and functional foods. This study investigated the metabolic fate of VVP in human gut microbiota and uncovered the pivotal role of Bacteroides thetaiotaomicron using in vitro fecal fermentation models. VVP selectively promoted B.
View Article and Find Full Text PDFGut microbiota and metabolites related intra-patient variability of tacrolimus pharmacokinetics predicted adverse one-year outcomes following kidney transplantation.
Int Immunopharmacol
September 2025
Transplantation Center, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Key Laboratory of Translational Research in Transplantation Medicine of National Health Commission, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Clinical Resea
Kidney transplantation (KT) is an effective treatment for end-stage renal disease, with over 90 % of recipients requiring lifelong tacrolimus (Tac). However, The Tac pharmacokinetics exhibit high intra-patient variability (IPV), posing significant challenges. This study included 102 KT recipients at our center from October 2022 to December 2023.
View Article and Find Full Text PDF